Progyny (PGNY) Competitors

Guardant Health (NASDAQ:GH) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.

Which has more risk and volatility, GH or PGNY?

Guardant Health has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of GH or PGNY?

92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 5.5% of Guardant Health shares are owned by company insiders. Comparatively, 12.3% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has preferable valuation and earnings, GH or PGNY?

Progyny has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$563.95M	9.39	-$479.45M	-$4.24	-10.11
Progyny	$1.09B	1.81	$62.04M	$0.58	40.00

Does the MarketBeat Community favor GH or PGNY?

Guardant Health received 187 more outperform votes than Progyny when rated by MarketBeat users. However, 71.13% of users gave Progyny an outperform vote while only 70.59% of users gave Guardant Health an outperform vote.

Company	Underperform	Outperform
Guardant Health	Outperform Votes 288 70.59%	Underperform Votes 120 29.41%
Progyny	Outperform Votes 101 71.13%	Underperform Votes 41 28.87%

Do analysts rate GH or PGNY?

Guardant Health currently has a consensus target price of $44.78, indicating a potential upside of 4.45%. Progyny has a consensus target price of $25.83, indicating a potential upside of 11.35%. Given Progyny's higher possible upside, analysts clearly believe Progyny is more favorable than Guardant Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	0 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	3.00
Progyny	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.31

Does the media refer more to GH or PGNY?

In the previous week, Guardant Health had 14 more articles in the media than Progyny. MarketBeat recorded 21 mentions for Guardant Health and 7 mentions for Progyny. Progyny's average media sentiment score of 0.95 beat Guardant Health's score of 0.54 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Progyny	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GH or PGNY more profitable?

Progyny has a net margin of 5.03% compared to Guardant Health's net margin of -74.02%. Progyny's return on equity of 11.36% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-74.02%	-1,200.44%	-29.88%
Progyny	5.03%	11.36%	7.87%

Summary

Progyny beats Guardant Health on 13 of the 18 factors compared between the two stocks.